Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4191-4200 Newer>

Managed Care September 2007 Martin Sipkoff	Go Carefully When Measuring Quality Gauging and rewarding good work in health care is a noble goal with potentially negative consequences.
Managed Care September 2007 Frank Diamond	Pay for Performance in Pharmacy Is More Theory Than Reality Even if the the goal of pay-for-performance pharmacy programs is unattainable in this country, working toward it might produce interesting experiments in cost efficiency.
Managed Care September 2007 Jaan Sidorov	Does the Chronic Care Model Signal Big Changes for DM? The pros and cons of disease management programs and the Chronic Care Model weigh heavily, but ultimately, a melding may benefit patients and primary care physicians.
Managed Care September 2007 Martin Sipkoff	Patent Law Rulings Work in Favor of Generics Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share.
The Motley Fool September 28, 2007 Brian Orelli	Free Drugs From Merck Merck plans to donate enough of its Gardasil vaccine to vaccinate one million women, in some of the poorest countries in the world, against the human papilloma virus.
The Motley Fool September 28, 2007 Brian Lawler	GSK Helps Secure Future of a Lead Drug GlaxoSmithKline settles a patent infringement case on a lead drug, Avandia, and with that challenger gone, the company is a step closer to securing one of its top franchises.
The Motley Fool September 28, 2007 Brian Lawler	Bioenvision Shareholder Battle Genzyme announces that it "cannot and will not" raise its $5.60-a-share bid for Bioenvision before shareholders go to vote on its proposed takeover. Investors, take note.
The Motley Fool September 28, 2007 Brian Orelli	Idenix Axes Ailing Initiatives The small drug developer drops its hepatitis B program, deciding instead to focus on its HCV and HIV drug development. Investors, take note.
The Motley Fool September 28, 2007 Brian Orelli	RNAi Doesn't Kill Mice After All From Merck, to AstraZeneca, to Novartis, big pharma continues to pump hundreds of millions of dollars into unproven RNAi technology. Investors, take note.
The Motley Fool September 28, 2007 Brian Orelli	Side Effects No Match for This Tag Team Seven large drugmakers have come together to try and find genetic variations that cause medications to have serious side effects in some patients, but not in others.
<Older 4191-4200 Newer> Return to current articles.